John T. Monyak

Cardiovascular Event Reduction and Adverse Events Among Subjects Attaining Low-Density Lipoprotein Cholesterol <50 mg/dl With Rosuvastatin

Judith Hsia, Jean MacFadyen, John T. Monyak et al. · Journal of the American College of Cardiology · 2011 · 232 citations

Pharmacy, Cardiology, Pharmacotherapy +14

Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial

Dick de Zeeuw, Deborah Anzalone, Valerie A. Cain et al. · The Lancet Diabetes & Endocrinology · 2015 · 162 citations

Medicine, Internal Medicine, Nephrology +14

Once-Weekly Exenatide in Youth With Type 2 Diabetes

William V. Tamborlane, Raafat Bishai, David H. Geller et al. · Diabetes Care · 2022 · 89 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Relationship between intragastric acid control and healing status in the treatment of moderate to severe erosive oesophagitis

Philip O. Katz, G.G. Ginsberg, Paul Hoyle et al. · Alimentary Pharmacology & Therapeutics · 2006 · 77 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +14

Comparison of Lipid-Modifying Efficacy of Rosuvastatin Versus Atorvastatin in Patients With Acute Coronary Syndrome (from the LUNAR Study)

Bertram Pitt, Joseph Loscalzo, John T. Monyak et al. · The American Journal of Cardiology · 2012 · 71 citations

Medicine, Cardiology, Pharmacology +15